Appointment Positions Company for Future Growth in Molecular Medicine

BOSTON, MA -- January 17, 2006 -- PerkinElmer, Inc. (NYSE: PKI), a leading provider of drug discovery, life science research, and analytical solutions, today announced its appointment of Dr. Karl Hecker as Director of Research & Development (R&D) for its Boston-based Center of Excellence. He will lead all product R&D efforts for the Center, which focuses on molecular medicine solutions for the company’s Life and Analytical Sciences unit. These solutions include chemistries, reagents, instruments and software serving the needs of customers engaged in areas such as proteomics, genomics and life sciences research.

Dr. Hecker joins PerkinElmer from Invitrogen and brings over 20 years of scientific experience in chemistry and biochemistry applications.

“Karl is a talented scientist and an innovative leader, and we are delighted to have him join our R&D team,” said Robert F. Friel, Vice Chairman, PerkinElmer Inc. “We are committed to adding strong domain knowledge to support our growth in the burgeoning areas of molecular medicine and this is an important step forward.”

Dr. Hecker holds a Ph.D. in biochemistry from Florida State University, a master’s of science degree in chemistry from Eastern Illinois University, and master’s and bachelor of science degrees in chemistry from Johann Wolfgang, Goethe University, Frankfurt Germany.

Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," “projects,” “forecasts,” "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our ability to identify a purchaser of the Company’s semiconductor business, negotiate and consummate the sale of such business, including obtaining regulatory approvals; (2) economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries; (3) risks related to our failure to introduce new products in a timely manner; (4) our ability to comply with financial covenants contained in our credit agreements and our debt instruments; (5) a delay in resolution of the Company’s tax audits and an adverse determination with respect to the Company’s tax audits by the Internal Revenue Service or other taxing authorities; (6) cyclical downturns continuing to affect several of the industries into which we sell our products; (7) our ability to adjust our operations to address unexpected changes; (8) our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business; (9) the loss of any of our licenses that may require us to stop selling products or lose competitive advantage; (10) competition; (11) regulatory compliance; (12) regulatory changes; (13) our failure to obtain and enforce intellectual property protection; (14) our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets; (15) other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.